Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.77 |
| ▸ | TUBB | P07437 | 4/20 | 0.77 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.77 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.77 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.77 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.77 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.77 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.77 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.77 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.77 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.77 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.77 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.77 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.77 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | P4HB | P07237 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715702 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14850589 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14922846 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16002088 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25801089 | 0.97 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12673500 | 0.97 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25854199 | 0.96 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16996785 | 0.96 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24226078 | 0.96 | TUBB4A (0.79) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20626989 | 0.96 | TUBB4A (0.79) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345786-B2 | Maytansinoid derivatives | BIO-THERA SOLUTIONS, LTD., CO. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20150151003-A1 | MAYTANSINOID DERIVATIVES | BIO THERA SOLUTIONS LTD CO (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20140178414-A1 | MAYTANSINOID DERIVATIVES | BIO-THERA SOLUTIONS, LTD., CO. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20140178411-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES | BIO-THERA SOLUTIONS, LTD., CO. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-8747851-B2 | Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same | IMMUNOGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8337855-B2 | Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same | IMMUNOGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110206700-A1 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME | IMMUNOGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178414-A1 | MAYTANSINOID DERIVATIVES | CD74, CD2BP2, CD2 | TUBB4A 1106/4885TUBB 1246/4885TUBA3C 3038/4885 |
| US-20150151003-A1 | MAYTANSINOID DERIVATIVES | CD74, CD2BP2, CD2 | TUBB4A 1106/4885TUBB 1246/4885TUBA3C 3038/4885 |
| US-20110206700-A1 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME | ENTPD3, CD47, FCGR3B | TUBB4A 2154/4885TUBB 2475/4885TUBA3C 1243/4885 |
| US-20140178411-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES | CD209, CD22, CD99 | TUBB4A 305/4885TUBB 480/4885TUBA3C 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.